Senior Correspondent, London
Ben's Feed
Feb 5, 2014

GlaxoSmithKline forecasts better 2014 as drug R&D improves

LONDON (Reuters) – GlaxoSmithKline has predicted a pick-up in sales growth to around 2 percent this year as productivity in its drug research labs improves and pressure on sales in China moderates following a damaging bribery scandal.

Britain’s biggest drugmaker also said on Wednesday that it would stay market leader in the respiratory medicine market – a category it has dominated since the launch of Ventolin in 1969 – despite generic threats to its top-selling Advair drug.

Feb 4, 2014
Feb 3, 2014
Jan 30, 2014
Jan 28, 2014
Jan 27, 2014
Jan 27, 2014

Emerging markets rout a reality check for Davos elite

DAVOS, Switzerland (Reuters) – Just as they were getting their swagger back, the global elite stumbled last week on an emerging market sell-off that served as a reminder of the risks the global economy still faces.

Veterans of the annual World Economic Forum in Davos seized on the wobble as a warning that expectations for a smooth upswing were misplaced, and that recovery would likely be volatile and uneven.

Jan 26, 2014
Jan 26, 2014

Analysis: Emerging markets rout a reality check for Davos elite

DAVOS, Switzerland (Reuters) – Just as they were getting their swagger back, the global elite stumbled last week on an emerging market sell-off that served as a reminder of the risks the global economy still faces.

Veterans of the annual World Economic Forum in Davos seized on the wobble as a warning that expectations for a smooth upswing were misplaced, and that recovery would likely be volatile and uneven.

Jan 25, 2014
    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben